Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD)

Itay Lotan; Gabriela Romanow; Rebecca Salky; Negar Molazadeh; Anastasia Vishnevetsky; Monique Anderson; Philippe Antoine Bilodeau; Gary Cutter; Michael Levy

doi:10.1002/acn3.51750

Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD)

Itay Lotan^*, Gabriela Romanow, Rebecca Salky, Negar Molazadeh, Anastasia Vishnevetsky, Monique Anderson, Philippe Antoine Bilodeau, Gary Cutter, Michael Levy

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort died, we estimated the upper limit of a 95% confidence interval of the crude mortality rate in the cohort to be 2.1%. These data suggest that mortality in MOGAD is lower than that reported in other neuroinflammatory diseases and comparable to the age-adjusted mortality rates of the general population in the United States. Additional studies are warranted to confirm this observation.

Original language	English
Pages (from-to)	664-667
Number of pages	4
Journal	Annals of Clinical and Translational Neurology
Volume	10
Issue number	4
DOIs	https://doi.org/10.1002/acn3.51750
State	Published - Apr 2023
Externally published	Yes

Access to Document

10.1002/acn3.51750

Cite this

@article{a3316702efd3463ebd543ce92f3b6402,

title = "Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD)",

abstract = "The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort died, we estimated the upper limit of a 95% confidence interval of the crude mortality rate in the cohort to be 2.1%. These data suggest that mortality in MOGAD is lower than that reported in other neuroinflammatory diseases and comparable to the age-adjusted mortality rates of the general population in the United States. Additional studies are warranted to confirm this observation.",

author = "Itay Lotan and Gabriela Romanow and Rebecca Salky and Negar Molazadeh and Anastasia Vishnevetsky and Monique Anderson and Bilodeau, {Philippe Antoine} and Gary Cutter and Michael Levy",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.",

year = "2023",

month = apr,

doi = "10.1002/acn3.51750",

language = "אנגלית",

volume = "10",

pages = "664--667",

journal = "Annals of Clinical and Translational Neurology",

issn = "2328-9503",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD)

AU - Lotan, Itay

AU - Romanow, Gabriela

AU - Salky, Rebecca

AU - Molazadeh, Negar

AU - Vishnevetsky, Anastasia

AU - Anderson, Monique

AU - Bilodeau, Philippe Antoine

AU - Cutter, Gary

AU - Levy, Michael

PY - 2023/4

Y1 - 2023/4

N2 - The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort died, we estimated the upper limit of a 95% confidence interval of the crude mortality rate in the cohort to be 2.1%. These data suggest that mortality in MOGAD is lower than that reported in other neuroinflammatory diseases and comparable to the age-adjusted mortality rates of the general population in the United States. Additional studies are warranted to confirm this observation.

AB - The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort died, we estimated the upper limit of a 95% confidence interval of the crude mortality rate in the cohort to be 2.1%. These data suggest that mortality in MOGAD is lower than that reported in other neuroinflammatory diseases and comparable to the age-adjusted mortality rates of the general population in the United States. Additional studies are warranted to confirm this observation.

UR - http://www.scopus.com/inward/record.url?scp=85149313950&partnerID=8YFLogxK

U2 - 10.1002/acn3.51750

DO - 10.1002/acn3.51750

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 36852731

AN - SCOPUS:85149313950

SN - 2328-9503

VL - 10

SP - 664

EP - 667

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

IS - 4

ER -

Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this